- Home
- ZWS vs BBIO Comparison
ZWS vs BBIO Comparison
Compare ZWS & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZWS
- BBIO
- Stock Information
- Founded
- ZWS 1891
- BBIO 2015
- Country
- ZWS United States
- BBIO United States
- Employees
- ZWS N/A
- BBIO N/A
- Industry
- ZWS Industrial Machinery/Components
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ZWS Industrials
- BBIO Health Care
- Exchange
- ZWS Nasdaq
- BBIO Nasdaq
- Market Cap
- ZWS 7.9B
- BBIO 9.4B
- IPO Year
- ZWS 2012
- BBIO 2019
- Fundamental
- Price
- ZWS $46.65
- BBIO $54.74
- Analyst Decision
- ZWS Buy
- BBIO Strong Buy
- Analyst Count
- ZWS 5
- BBIO 16
- Target Price
- ZWS $43.00
- BBIO $64.44
- AVG Volume (30 Days)
- ZWS 1.0M
- BBIO 2.0M
- Earning Date
- ZWS 10-28-2025
- BBIO 11-11-2025
- Dividend Yield
- ZWS 0.76%
- BBIO N/A
- EPS Growth
- ZWS 30.58
- BBIO N/A
- EPS
- ZWS 1.01
- BBIO N/A
- Revenue
- ZWS $1,614,000,000.00
- BBIO $235,812,000.00
- Revenue This Year
- ZWS $7.44
- BBIO $115.46
- Revenue Next Year
- ZWS $4.10
- BBIO $65.03
- P/E Ratio
- ZWS $47.06
- BBIO N/A
- Revenue Growth
- ZWS 4.74
- BBIO 7.62
- 52 Week Low
- ZWS $27.74
- BBIO $21.72
- 52 Week High
- ZWS $48.42
- BBIO $55.32
- Technical
- Relative Strength Index (RSI)
- ZWS 52.65
- BBIO 60.43
- Support Level
- ZWS $46.40
- BBIO $52.97
- Resistance Level
- ZWS $47.76
- BBIO $55.33
- Average True Range (ATR)
- ZWS 0.77
- BBIO 1.55
- MACD
- ZWS -0.11
- BBIO 0.21
- Stochastic Oscillator
- ZWS 52.66
- BBIO 90.53
About ZWS Zurn Elkay Water Solutions Corporation
Zurn Elkay Water Solutions Corp designs procures, manufactures, and markets a range of clean water solutions for drinking water, hygiene, and sustainable water management. The company's product portfolio includes professional-grade water control and safety, water distribution and drainage, drinking water, finish plumbing, hygienic, environmental and site works products for public and private spaces.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.